Publication Activity (10 Years)
Years Active: 2018-2024
Publications (10 Years): 6
Publications (10 Years): 6
Arvinas (United States)
Rockefeller University (PHD)
Affiliation History
Arvinas (United States)
Sep 09 2019
United States
Principal Research Investigator
Hartford Hospital
Feb 02 2015
- Aug 30 2019
United States
Senior Scientist :: Research
Bristol-Myers Squibb Co
Apr 10 2004
- May 31 2014
United States
Principal Scientist :: Applied Genomics
AstraZeneca Pharmaceuticals LP
Dec 01 2000
- Feb 28 2004
United States
Scientist
Education History
Rockefeller University
Jun 01 1992
- Apr 15 1997
United States
PHD
Columbia University
Sep 01 1983
- May 05 1987
United States
BSC :: School of Engineering and Applied Science
Publications
- Sheryl M Gough, John J Flanagan, Jessica L F Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Deborah Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John P Corradi, Katherine M Digianantonio, Ieva Drulyte, Alicia Morgan, Connor Quinn, Miklós Békés, Caterina Ferraro, Xin Chen, Gan Wang, Hanqing Dong, Jing Wang, David R Langley, John Houston, Richard Gedrich, Ian C TaylorOral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
- Sheryl M Gough, John J Flanagan, Jessica L F Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Deborah Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John P Corradi, Katherine M Digianantonio, Ieva Drulyte, Alicia Morgan, Connor Quinn, Miklós Békés, Caterina Ferraro, Xin Chen, Gan Wang, Hanqing Dong, Jing Wang, David R Langley, John Houston, Richard Gedrich, Ian C Taylor
- Sheryl M Gough, John J Flanagan, Jessica L F Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Deborah Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John P Corradi, Katherine M Digianantonio, Ieva Drulyte, Alicia Morgan, Connor Quinn, Miklós Békés, Caterina Ferraro, Xin Chen, Gan Wang, Hanqing Dong, Jing Wang, David R Langley, John Houston, Richard Gedrich, Ian C TaylorOral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
- Sheryl M Gough, John J Flanagan, Jessica L F Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Deborah Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John P Corradi, Katherine M Digianantonio, Ieva Drulyte, Alicia Morgan, Connor Quinn, Miklós Békés, Caterina Ferraro, Xin Chen, Gan Wang, Hanqing Dong, Jing Wang, David R Langley, John Houston, Richard Gedrich, Ian C TaylorOral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
- Sheryl M Gough, John J Flanagan, Jessica L F Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Deborah Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John P Corradi, Katherine M Digianantonio, Ieva Drulyte, Alicia Morgan, Connor Quinn, Miklós Békés, Caterina Ferraro, Xin Chen, Gan Wang, Hanqing Dong, Jing Wang, David R Langley, John Houston, Richard Gedrich, Ian C TaylorOral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
- John P Corradi, Stephen Thompson, Jeffrey F Mather, Christine M Waszynski, Robert S Dicks